Clinical Trials

NCT Number: NCT05054296 Phase: Phase 2 Trial Summary: This phase II trial studies how well an exercise program and continuous Fitbit monitoring work for managing metabolic syndrome and cardiovascular disease risk in patients with pros – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center|National Cancer Institute (NCI) Acronym:

NCT Number: NCT05075577 Phase: Phase 1|Phase 2 Trial Summary: This is a Phase 1/2 study of EPI-7386 orally administered in combination with enzalutamide in subjec – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): ESSA Pharmaceuticals Acronym:

NCT Number: NCT05050084 Phase: Phase 3 Trial Summary: This phase III trial uses the Decipher risk score to guide intensification (for higher Decipher gene risk) or de-intensification (for low Decipher gene risk) of treatment to better – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): NRG Oncology|National Cancer Institute (NCI) Acronym:

NCT Number: NCT05038332 Phase: Phase 2 Trial Summary: The primary purpose of this study is to compare the quality of life (QOL) reported by prostate cancer patients 2 years after treatment with ultra-hypofractionated post-prostatectom – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): University of Michigan Rogel Cancer Center Acronym:

NCT Number: NCT05043012 Phase: Not Applicable Trial Summary: Multiparametric MRI (mpMRI) of the prostate is an important tool for diagnosis of clinically significant prostate cancer (csPCa) in men with an elevated serum prostate specific ant – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): M.D. Anderson Cancer Center Acronym:

NCT Number: NCT05011383 Phase: Phase 2 Trial Summary: This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): VA Office of Research and Development […]

NCT Number: NCT05027477 Phase: Not Applicable Trial Summary: Men with localized, intermediate risk prostate cancer will be randomized to undergo either radical prostatectomy or the TULSA procedure, with a follow-up of 10 years in this multi- – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Profound Medical Inc. Acronym: CAPTAIN

NCT Number: NCT05036226 Phase: Phase 1|Phase 2 Trial Summary: The purpose of this Phase I/II study is to determine the safety and effectiveness of up to 5 study drugs used together for the treatment of solid tumor cancers. The drugs are hydro – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Medical University of […]

NCT Number: NCT04997018 Phase: Phase 2 Trial Summary: One of the usual approaches to treating intermediate-risk prostate cancer is a type of radiation therapy called SBRT (stereotactic body radiation therapy). SBRT delivers higher tha – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Memorial Sloan Kettering Cancer Center Acronym:

NCT Number: NCT05005728 Phase: Phase 2 Trial Summary: This Phase 2 study will investigate the safety and clinical activity of vudalimab (XmAb20717) alone or in combination with standard of care anticancer therapies in patients with me – clinicaltrials.gov for more information and locations Clinicaltrials.gov Trial Sponsor(s): Xencor, Inc. Acronym: